Abstract
Axicabtagen ciloleucel and tisagenlecleucel are two gene therapies that contain
T-lymphocytes of the patient previously manipulated so they express themselves
membrane, chimeric antigenic receptor or CAR. This receiver allows the recognition of CD19 lymphocyte antigen, both malignant B lymphocytes and no malignant Both therapies differ in the co-stimulator and in the intracellular domain viral vector used for gene transduction.
Keywords
B-cell lymphoma; Axicabtagen ciloleucel; Tisagenclecleucel
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Axicabtagen ciloleucel i tisagenlecleucel per al tractament del limfoma B de cèl·lules grans. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4273This item appears in following collections
The following license files are associated with this item: